Biomarin Pharmaceutical Inc [BMRN] stock is trading at $60.31, up 3.73%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The BMRN shares have gain 3.73% over the last week, with a monthly amount glided 4.89%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Oppenheimer upgraded its rating to Outperform on February 24, 2025, and kept the price target unchanged to $98. On November 15, 2024, Wolfe Research initiated with a Outperform rating and assigned a price target of $95 on the stock. William Blair downgraded its rating to a Mkt Perform. Bernstein upgraded its rating to Outperform for this stock on August 20, 2024, and upped its price target to $110. In a note dated May 17, 2024, Robert W. Baird downgraded an Neutral rating on this stock and revised its target price from $104 to $72.
Biomarin Pharmaceutical Inc [BMRN] stock has fluctuated between $52.93 and $94.85 over the past year. Currently, Wall Street analysts expect the stock to reach $95 within the next 12 months. Biomarin Pharmaceutical Inc [NASDAQ: BMRN] shares were valued at $60.31 at the most recent close of the market. An investor can expect a potential return of 57.52% based on the average BMRN price forecast.
Analyzing the BMRN fundamentals
Biomarin Pharmaceutical Inc [NASDAQ:BMRN] reported sales of 3.04B for the trailing twelve months, which represents a growth of 16.48%. Gross Profit Margin for this corporation currently stands at 0.79% with Operating Profit Margin at 0.21%, Pretax Profit Margin comes in at 0.23%, and Net Profit Margin reading is 0.18%. To continue investigating profitability, this company’s Return on Assets is posted at 0.07, Equity is 0.09 and Total Capital is 0.09. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.1.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Biomarin Pharmaceutical Inc’s Current Ratio is 5.56. As well, the Quick Ratio is 3.60, while the Cash Ratio is 1.67. Considering the valuation of this stock, the price to sales ratio is 3.81, the price to book ratio is 1.92 and price to earnings (TTM) ratio is 17.86.
Transactions by insiders
Recent insider trading involved Burkhart Erin, GVP, Chief Accounting Officer, that happened on May 20 ’25 when 1786.0 shares were sold. Officer, Burkhart Erin completed a deal on May 20 ’25 to buy 1786.0 shares. Meanwhile, EVP, Chief Commercial Officer Hubbard Cristin sold 273.0 shares on May 02 ’25.
